Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
14.21
-0.21 (-1.46%)
At close: Apr 25, 2025, 4:00 PM
14.15
-0.06 (-0.42%)
Pre-market: Apr 28, 2025, 7:44 AM EDT
Keros Therapeutics Revenue
In the year 2024, Keros Therapeutics had annual revenue of $3.55M with 2,250.99% growth. Keros Therapeutics had revenue of $3.04M in the quarter ending December 31, 2024, with 2,027.27% growth.
Revenue (ttm)
$3.55M
Revenue Growth
+2,250.99%
P/S Ratio
149.86
Revenue / Employee
$21,006
Employees
169
Market Cap
576.39M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
KROS News
- 17 days ago - Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan - Benzinga
- 17 days ago - Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
- 18 days ago - Keros Therapeutics adopts 'poison pill' plan - Reuters
- 18 days ago - Keros Therapeutics Announces Review of Strategic Alternatives - GlobeNewsWire
- 4 weeks ago - Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 2 months ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Accesswire